TY - JOUR
T1 - The burden of vulvovaginal atrophy on women's daily living: Implications on quality of life from a face-to-face real-life survey
AU - Nappi, R.E.
AU - Palacios, S.
AU - Bruyniks, N.
AU - Particco, M.
AU - Panay, N.
N1 - Cited By :6
Export Date: 10 October 2019
CODEN: MENOF
Correspondence Address: Nappi, R.E.; Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, University of Pavia, Piazzale Golgi 2, Italy; email: renappi@tin.it
Funding details: Shionogi
Funding text 1: Acknowledgments: Manuscript writing and editorial support was provided by Emili González-Pérez, PhD of TFS, S.L., with financial support provided by Shionogi Ltd. The study was sponsored by Shionogi Ltd. The complete list of EVES Study investigators is as follows: C. Argudo Prieto (Gijón, Spain), L. Baquedano Mainar (Zaragoza, Spain), A.M. Becorpi (Firenze, Italy), P. Benedetti Panici (Roma, Italy), C. Benedetto (Torino, Italy), N. Biglia (Torino, Italy), M. Busacca (Milano, Italy), A. Cagnacci (Modena, Italy), J. Calleja Abu-Amshah (Madrid, Spain), M.J. Cancelo Hidalgo (Guadalajara, Spain), C. Castelo Branco i Flores (Barcelona, Spain), A. Cianci (Catania, Italy), E. Cicinelli (Bari, Italy), P. Coronado Martin (Madrid, Spain), M. Correa Rancel (Santa Cruz de Tenerife, Spain), F. De Seta (Trieste, Italy), C. Di Carlo (Napoli, Italy), M. Fernández Abellán (Málaga, Spain), J.M. Fernández Moya (Madrid, Spain), M. Gambacciani (Pisa, Italy), P. García Alfaro (Barcelona, Spain), M. González Fernández (Barcelona, Spain), S. González Rodríguez (Madrid, Spain), M. Guida (Salerno, Italy), E. Iglesias Bravo (Sevilla, Spain), P. Llaneza Coto (Oviedo, Spain), S. Luisi (Siena, Italy), M. Manubens Grau (Barcelona, Spain), D. Marchesoni (Udine, Italy), P. Marín Sánchez (El Palmar, Spain), N. Mendoza Ladrón de Guevara (Granada, Spain), R.E. Nappi (Pavia, Italy), B. Otero García-Ramos (Baracaldo, Spain), A.M. Paoletti (Cagliari, Italy), S. Palacios (Madrid, Spain), A. Pellegrino (Lecco, Italy), J.C. Presa Lorite (Jaén, Spain), V. Remorgida (Genova, Italy), S. Salvatore (Milano, Italy), R. Sánchez Borrego (Barcelona, Spain), S. Sánchez Méndez (Sant Cugat del Vallés, Spain), R. Seracchioli (Bologna, Italy), M. Stomati (Brindisi, Italy), N. Surico (Novara, Italy), F. Vázquez Fernández (Lugo, Spain), and P. Villa (Roma, Italy).
References: Bachmann, G.A., Nevadunsky, N.S., Diagnosis and treatment of atrophic vaginitis (2000) Am Fam Physician, 61, pp. 3090-3096; Castelo-Branco, C., Cancelo, M.J., Villero, J., Nohales, F., Juliá, M.D., Management of post-menopausal vaginal atrophy and atrophic vaginitis (2005) Maturitas, 52, pp. S46-S52; Pandit, L., Ouslander, J.G., Postmenopausal vaginal atrophy and atrophic vaginitis (1997) Am J Med Sci, 314, pp. 228-231; Gass, M., Larson, J., Cochrane, B., Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials (2018) Menopause, 25, pp. 252-264; Freedman, M.A., Vaginal pH, estrogen and genital atrophy (2008) Menopause Manag, 17, pp. 9-13; Nappi, R.E., Palacios, S., Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause (2014) Climacteric J Int Menopause Soc, 17, pp. 3-9; Parish, S.J., Nappi, R.E., Krychman, M.L., Impact of vulvovaginal health on postmenopausal women: A review of surveys on symptoms of vulvovaginal atrophy (2013) J Womens Health, 5, pp. 437-447; Levine, K.B., Williams, R.E., Hartmann, K.E., Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women (2008) Menopause, 15, pp. 661-666; Nappi, R.E., Kingsberg, S., Maamari, R., Simon, J., The closer (clarifying vaginal atrophy's impact on sex and relationships) survey: Implications of vaginal discomfort in postmenopausal women and in Male partners (2013) J Sex Med, 10, pp. 2232-2241; Freedman, M.A., Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: Findings from the REVIVE survey (2014) Womens Health Lond Engl, 10, pp. 445-454; Nappi, R.E., Kokot-Kierepa, M., Women's voices in the menopause: Results from an international survey on vaginal atrophy (2010) Maturitas, 67, pp. 233-238; Gandhi, J., Chen, A., Dagur, G., Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management (2016) Am J Obstet Gynecol, 215, pp. 704-711; Nappi, R.E., Palacios, S., Panay, N., Particco, M., Krychman, M.L., Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey (2016) Climacteric, 19, p. 188; Nappi, R.E., Kokot-Kierepa, M., Vaginal Health: Insights, Views &Attitudes (VIVA)-results from an international survey (2012) Climacteric J Int Menopause Soc, 15, pp. 36-44; Nappi, R.E., Cucinella, L., Martella, S., Rossi, M., Tiranini, L., Martini, E., Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL) (2016) Maturitas, 94, pp. 87-91; Latif, E.Z., Diamond, M.P., Arriving at the diagnosis of female sexual dysfunction (2013) Fertil Steril, 100, pp. 898-904; DiBonaventura, M., Luo, X., Moffatt, M., Bushmakin, A.G., Kumar, M., Bobula, J., The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe (2015) J Womens Health (Larchmt), 24, pp. 713-722; Lang, K., Alexander, I.M., Simon, J., The impact of multimorbidity on quality of life among midlife women: Findings from a U. S (2015) Nationally Representative Survey. J Womens Health (Larchmt), 24, pp. 374-383; Palacios, S., Nappi, R.E., Bruyniks, N., Particco, M., Panay, N., The European Vulvovaginal Epidemiological Survey (EVES): Prevalence, symptoms and impact of vulvovaginal atrophy of menopause (2018) Climacteric J Int Menopause Soc, 21, pp. 286-291. , EVES Study Investigators; EuroQol-A new facility for the measurement of healthrelated quality of life (1990) Health Policy Amst Neth, 16, pp. 199-208. , EuroQol Group; (2013) Menopause, 20, pp. 888-902. , Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society; Gass, M.L.S., Cochrane, B.B., Larson, J.C., Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative (2011) Menopause, 18, pp. 1160-1171; Utian, W.H., Maamari, R., Attitudes and approaches to vaginal atrophy in postmenopausal women: A focus group qualitative study (2014) Climacteric, 17, pp. 29-36; Huang, A.J., Gregorich, S.E., Kuppermann, M., Day-to-Day Impact of Vaginal Aging questionnaire: A multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women (2015) Menopause, 22, pp. 144-154; Hunter, M.M., Nakagawa, S., Van Den Eeden, S.K., Kuppermann, M., Huang, A.J., Predictors of impact of vaginal symptoms in postmenopausal women (2016) Menopause, 23, pp. 40-46
PY - 2019
Y1 - 2019
N2 - Objective:This subanalysis of the European Vulvovaginal Epidemiology Survey study aimed to assess the correlation of vulvovaginal atrophy (VVA) symptoms and severity, when confirmed by objective gynecologic examination, with the quality of life of postmenopausal women.Methods:Women aged 45 to 75 years with confirmation of last menstrual period more than 12 months before, who attended menopause or gynecology centers, were included. Those women had at least one VVA symptom filled in a group of questionnaires, including EuroQol-EQ-5D-3L and Day-to-Day Impact of Vaginal Aging (DIVA). To confirm the VVA diagnosis, an objective gynecologic examination was also performed.Results:Of a total of 2,160 evaluable women, 66.3%, 30.5%, and 11.2% suffered from severe vaginal, vulvar, and urinary symptoms, respectively. VVA was confirmed in more than 90% of the participants. Mean (±SD) EQ-5D-3L score was 0.892 ± 0.144 and mean (±SD) score on the associated visual analog scale was 71.7 ± 16.0. Mean (±SD) DIVA score was 0.922 ± 0.653. For both EQ-5D-3L and DIVA, the overall scores and most of the dimensions/components were statistically significantly worse for women with severe VVA symptoms (vulvar and urinary) compared with women not affected by severe symptoms. Quality of life questionnaires showed worse scores in women where the diagnosis of VVA was confirmed by gynecologic examination.Conclusions:Severe VVA symptoms showed a direct association with worse quality of life in postmenopausal women. This important effect on the quality of life of many women should be recognized as equivalent to those from other conditions and pathologies of which there is greater awareness. © 2019 Lippincott Williams and Wilkins. All rights reserved.
AB - Objective:This subanalysis of the European Vulvovaginal Epidemiology Survey study aimed to assess the correlation of vulvovaginal atrophy (VVA) symptoms and severity, when confirmed by objective gynecologic examination, with the quality of life of postmenopausal women.Methods:Women aged 45 to 75 years with confirmation of last menstrual period more than 12 months before, who attended menopause or gynecology centers, were included. Those women had at least one VVA symptom filled in a group of questionnaires, including EuroQol-EQ-5D-3L and Day-to-Day Impact of Vaginal Aging (DIVA). To confirm the VVA diagnosis, an objective gynecologic examination was also performed.Results:Of a total of 2,160 evaluable women, 66.3%, 30.5%, and 11.2% suffered from severe vaginal, vulvar, and urinary symptoms, respectively. VVA was confirmed in more than 90% of the participants. Mean (±SD) EQ-5D-3L score was 0.892 ± 0.144 and mean (±SD) score on the associated visual analog scale was 71.7 ± 16.0. Mean (±SD) DIVA score was 0.922 ± 0.653. For both EQ-5D-3L and DIVA, the overall scores and most of the dimensions/components were statistically significantly worse for women with severe VVA symptoms (vulvar and urinary) compared with women not affected by severe symptoms. Quality of life questionnaires showed worse scores in women where the diagnosis of VVA was confirmed by gynecologic examination.Conclusions:Severe VVA symptoms showed a direct association with worse quality of life in postmenopausal women. This important effect on the quality of life of many women should be recognized as equivalent to those from other conditions and pathologies of which there is greater awareness. © 2019 Lippincott Williams and Wilkins. All rights reserved.
KW - DIVA
KW - EQ-5D-3L
KW - Gynecologic examination
KW - Menopause
KW - Quality of life
KW - Vulvovaginal atrophy
U2 - 10.1097/GME.0000000000001260
DO - 10.1097/GME.0000000000001260
M3 - Article
VL - 26
SP - 485
EP - 491
JO - Menopause
JF - Menopause
SN - 1072-3714
IS - 5
ER -